HIV and AIDS Research News & Events
Learn about upcoming meetings relevant to HIV malignancies and recent news about NCI HIV/AIDS and HIV malignancy research.
The National Institutes of Health Office of AIDS Research (OAR) joins colleagues worldwide to commemorate to 40th anniversary of the landmark 1981 Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) that first recognized the syndrome of diseases as later named AIDS. Below are two MMWR relevant articles.
Learn how the AIDS and Cancer Specimen Resource (ACSR) developed new strategies to improve visibility by using a cross disciplinary approach.
Collaborating with a Graduate Marketing Class to Boost Awareness of the AIDS and Cancer Specimen Resource
Biopreservation and Biobanking
In celebration of World AIDS Day 2020, Dr. Robert Yarchoan provided a reflection on the history of HIV drugs developed at NCI, on HIV malignancies, and how HIV research is informing research on drugs against COVID.
Researchers in the HIV and AIDS Malignancy Branch, CCR reported trial results showing that treatment of aggressive HIV-associated primary central nervous lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate is associated with high response rate, CD4+ lymphocyte reconstitution, and long-term survival with preservation or improvement of neurocognitive function.
Treatment of HIV-associate Primary CNS Lymphoma with Antiretroviral Therapy, Rituximab, and High-Dose Methotrexate
On May 14, 2020 FDA approves pomalidomide for AIDSrelated Kaposi sarcoma. The approval of Pomalyst was as a result of a Phase 1/2 clinical trial in patients with HIV-positive and HIV-negative symptomatic Kaposi sarcoma conducted by a team led by Dr. Robert Yarchoan of the HIV and AIDS Malignancy Branch.
Results from a large clinical trial supported by NCI and NIAID demonstrated that patients with advanced AIDS-associated Kaposi sarcoma have
improved outcomes when treated with antiretroviral therapy and the chemotherapy drug paclitaxel.
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial
The NIH Record highlighted the 25th Anniversary of Kaposi sarcoma-associated herpesvirus (KSHV) which was celebrated at the 17th International Conference on Malignancies in HIV/AIDS. At the meeting Dr. Douglas Lowy, then acting director of NCI, presented the NCI Director's award to Drs. Patrick Moore and Yuan Chang for their discovery two of the known oncogenic viruses (KSHV and Merkel cell polyomavirus) and their research to elucidate the biology of these viruses.
Read about Dr. Robert Yarchoan and the Office of HIV and AIDS Malignancy. This article highlights OHAM's efforts in HIV/AIDS malignancy research.
Researchers from NCI and the Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab.
Researchers from the AIDS Malignancy Consortium have completed a cervical cancer trial in sub-Saharan Africa showing that women living with HIV can be treated with concomitant chemoradiotherapy using the same dose as HIV-negative women.
Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS Malignancy Consortium
Researchers at NCI have demonstrated that cytokine dysregulation is a hallmark of primary effusion lymphoma pathogenesis, symptom profile and natural history.
The latest information on the epidemiological, clinical features and treatment options for Kaposi sarcoma is highlighted in this review.
Nature Reviews Disease Primers
KSHV 2021 Virtual Meeting June 21-24, 2021 Registered participants will have On-Demand access to oral and iPoster sessions through July 10, 2021 The NIH World AIDS Day virtual event: Science and Community: Working to Prepare for the Unexpected Tuesday, December 1, 2020 To be videocast live from 11:00 AM to 12:30 PM EST